IDXXHealthcare · Diagnostics & ResearchThe 14 Wall Street analysts covering IDEXX Laboratories, Inc. hold a median 12-month price target of $700 — +35.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 8 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores IDEXX Laboratories, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (99): The business earns solid, repeatable profits on what it owns.
Momentum (48): The shares have been drifting down relative to others.
Size (6): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IDXX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +35.9% from it.
Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | Barclays | Maintains | Overweight | $800 → $710 |
| 5 Aug 2026 | Citigroup | Maintains | Neutral | $650 → $670 |
| 5 Aug 2026 | UBS | Maintains | Neutral | $620 → $670 |
| 27 July 2026 | UBS | Maintains | Neutral | — |
| 27 July 2026 | UBS | Maintains | Neutral | $640 → $620 |
| 28 Apr 2026 | UBS | Maintains | Neutral | $730 → $640 |
| 28 Apr 2026 | UBS | Maintains | Neutral | — |
| 15 Apr 2026 | Citigroup | Initiates | Neutral | — |
| 31 Mar 2026 | Stifel | Maintains | Buy | — |
| 9 Feb 2026 | Piper Sandler | Maintains | Neutral | — |
| 5 Feb 2026 | Barclays | Maintains | Overweight | — |
| 3 Feb 2026 | BTIG | Maintains | Buy | — |
| 3 Feb 2026 | UBS | Maintains | Neutral | — |
| 9 Dec 2025 | Barclays | Initiates | Overweight | — |
| 4 Nov 2025 | BTIG | Maintains | Buy | — |
| 4 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 4 Nov 2025 | Morgan Stanley | Maintains | Overweight | — |
| 4 Nov 2025 | UBS | Maintains | Neutral | — |
| 31 Oct 2025 | Stifel | Upgrade | Buy | — |
| 1 Oct 2025 | UBS | Initiates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IDXX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 9 Sept 2026, IDEXX Laboratories, Inc. returned −21.4% against +18.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 20% of US stocks
Cheaper than 15% of US stocks
Cheaper than 4% of US stocks
Cheaper than 10% of US stocks
Higher than 51% of US stocks
Higher than 53% of US stocks
Higher than 77% of US stocks
Higher than 89% of US stocks
Higher than 86% of US stocks
Higher than 95% of US stocks
Higher than 99% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
IDEXX Laboratories, Inc. has a market value of $40.6B and an enterprise value of $41.5B.
Revenue in the twelve months to 30 June 2026: $4.6B. The latest quarter grew 9.7% year on year.
Net income over the same four quarters: $1.1B, a 25.0% net margin.
Diluted earnings per share, trailing twelve months: $14.22.
Free cash flow in the twelve months to 30 June 2026: $1.2B.
IDEXX Laboratories, Inc. spent $1.2B on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 36.5×; forward P/E: 30.8× — the forward figure prices analyst consensus estimates, not reported earnings.
IDEXX Laboratories, Inc. employs 11,000 people — $414K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own IDEXX Laboratories, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Idexx reported earnings 30 days ago, and its stock has fallen 7.8% since that report. The piece questions what comes next for the stock and whether it can rebound.
Why it matters — A IDXX watcher would care because the item tracks the stock's post-earnings decline and raises the question of whether it can recover.
Baron Focused Growth Fund rebounded in Q2 2026, gaining 13.26% versus 24.02% for the Russell 2500 Growth Index, and ended the period with 28 investments. The fund reiterated its long-term focus on competitively advantaged growth businesses.
Why it matters — This update may be relevant to IDEXX watchers if the company is among the fund's 28 holdings, signaling institutional investor confidence, though the excerpt provides no specific mention of IDEXX.
IDEXX Laboratories announced that CEO Mike Erickson and CFO Andrew Emerson will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, from 10:45am to 11:20am ET. A live audio webcast of the session will be available.
Why it matters — The fireside chat gives investors an opportunity to hear directly from IDEXX's top executives about the company at a major healthcare investment conference.
Zacks Investment Research highlights Idexx Laboratories as a top-ranked growth stock based on its Style Scores system, which is designed to help investors identify strong, market-beating stocks. The piece frames IDXX as a standout candidate within this framework.
Why it matters — This item matters to IDXX watchers because it indicates the stock is being recognized favorably by a widely followed quantitative ranking methodology.
Zacks Investment Research has highlighted Idexx Laboratories (IDXX) as a strong momentum stock, citing its Zacks Style Scores — a feature of the Zacks Premium research service — as a tool that helps investors identify strong stocks regardless of investing style.
Why it matters — An IDXX watcher would care because a positive momentum designation from Zacks reflects the stock's favourable ranking among peers and draws attention within the investment community.
The 14 Wall Street analysts covering IDEXX Laboratories, Inc. have a median 12-month price target of $700, with estimates ranging from $470 to $805. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering IDEXX Laboratories, Inc., 8 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks IDEXX Laboratories, Inc. 92 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Sept 2026, IDEXX Laboratories, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +35.9% from the last close, and Ticker Nerd's factor model ranks IDEXX Laboratories, Inc. 92 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering IDEXX Laboratories, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IDXX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $470 to $805 over the next 12 months.
IDEXX Laboratories, Inc. returned -21.4% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
IDEXX Laboratories, Inc. is a global diagnostics and software company focused on animal health, water quality, and agricultural testing.
The most recent item we track (Zacks Investment Research, 3 Sept 2026): "Idexx (IDXX) Down 7.8% Since Last Earnings Report: Can It Rebound?". Idexx reported earnings 30 days ago, and its stock has fallen 7.8% since that report. The piece questions what comes next for the stock and whether it can rebound.
IDEXX Laboratories, Inc. is a global diagnostics and software company focused on animal health, water quality, and agricultural testing. IDEXX Laboratories, Inc. develops and supplies in-clinic veterinary diagnostic instruments, consumable test kits, reference laboratory services, and practice management software that help veterinarians diagnose and monitor companion animals. The company also provides testing solutions for livestock, poultry, and dairy producers, along with water microbiology products used to assess drinking water safety and quality. Its product portfolio is built around recurring consumables, laboratory workflows, and integrated software tools that support everyday clinical and operational decisions. IDEXX Laboratories, Inc. serves veterinary practices, animal health professionals, utilities, and food-production customers across global markets, making it an important provider of diagnostic infrastructure in the broader healthcare and environmental testing ecosystem.
CEO Mr. Michael G. Erickson Ph.D. · 11,000 employees · United States · https://www.idexx.com
